The Weight Loss Drug Race Heats Up: Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Trials

Eli Lilly's Zepbound has outperformed Novo Nordisk's Wegovy in weight loss trials. Zepbound targets adults with obesity and comorbidities.